- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07633886
Multi-Centre Based Evaluation of the Performance and Safety of the Corsano CardioWatch 287-2 Blood Pressure Monitoring Device at Wrist Against BP-Cuff Measurements (COR-BP) (COR-BP)
The Corsano CardioWatch 287-2 is a medical wearable device that can monitor blood pressure. The device has been validated using clinical trials in hospitals. The aim of this study is to further evaluate blood pressure measurements by the CardioWatch 287-2 in the intended remote setting across various demographic groups.
Primary objective: To assess the difference in blood pressure measurements obtained by the Corsano CardioWatch 287-2 and auscultatory blood pressure monitoring over a period of 31 days.
Secondary objective: To assess the usability of the Corsano CardioWatch 287-2 from a patient perspective.
Participants receiving multiple standardized paired auscultatory and Corsano CardioWatch blood pressure measurements over a 31-day period. The study group will include patients of different ages (above the age of 22 years), genders, and demographics.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Nova Jaspers, MSc
- Telefonní číslo: +31616407778
- E-mail: nova.jaspers@corsano.com
Studijní záloha kontaktů
- Jméno: Elena Ferraris, MSc
- E-mail: elena@corsano.com
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Participants must be able to provide informed consent to participate.
- Participants must be willing and able to comply with all of the study procedures and return for at least 3 visits.
- Participant or witness must be able to read or write in Dutch or English.
- Applicable for group A: Participant must be 22 to 50 years of age.
- Applicable for group B: Participant must be over 50 years of age.
Exclusion Criteria:
- Participants with compromised circulation, injury, or physical malformation of the equipment test sites or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized).
- Female participants who are known to be pregnant or who are trying to get pregnant confirmed by a day 1 positive urine pregnancy test unless the study participant is known to be not of child-bearing potential.
- Participants with known clotting disorders or currently taking a prescription blood thinner.
- Other known health conditions that will prevent safe participation in the study upon disclosure in Health Assessment Short Form or verbally.
- Participants suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including tachycardia (heart rate at rest > 120bpm) and atrial fibrillation.
- Participants suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR < 60mL / min / 1.73 m2), hyper- / hypothyroidism, pheochromocytoma or arteriovenous fistula.
- Participants with known aortic arch pathology or prior surgical intervention involving the aortic arch or descending aorta (e.g., coarctation repair, vascular grafting, or stenting), which may interfere either with accurate peripheral blood pressure measurement.
- A wrist circumference below 14 cm or above 23 cm.
- An upper arm circumference < 22cm or > 42cm.
- Any subject that, in the opinion of the investigator, does not exhibit any phenotype relevant to the objectives of this study (i.e. to ensure all sub-groups have adequate representation).
- Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, bias the results, by instance a subject presenting a lateral Blood Pressure difference at screening of more than 15 mmHg for the systolic and/or more than 10 mmHg for the diastolic.
Additional criteria that will be pursued for ensuring demographic diversity consist of the following patient characteristics according to FDA recommendations concerning the diversity of clinical trial populations [6]:
Gender, at least:
- 40% female;
- 40% male.
Skin Colour, at least:
- 25% Monk skin tone (MST) 1-3;
- 25% MST 4-6;
- 25% MST 7-10 including subjects with MST 9 and MST 10.
BMI, at least:
- 5% Underweight (<18.5)
- 20% Normal weight (18.5-24.9)
- 20% Overweight (25-29.9)
- 20% Obese (≥30.0)
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Group A
Group A consists of patients 22 to 50 years of age.
Group A involves patients from multiple demographic groups.
|
Non-invasive blood pressure measurements with the Corsano CardioWatch 287-2 wearable over a period of 31 days.
Ostatní jména:
Auscultatory blood pressure measurements in supine and sitting position.
|
|
Group B
Group B consists of patients aged 50 years and above.
Group B involves patients from multiple demographic groups.
|
Non-invasive blood pressure measurements with the Corsano CardioWatch 287-2 wearable over a period of 31 days.
Ostatní jména:
Auscultatory blood pressure measurements in supine and sitting position.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Validate blood pressure measurements Corsano CardioWatch 287-2
Časové okno: 31 days
|
The main objective of this study is to assess the difference in blood pressure measurements obtained by the Corsano CardioWatch 287-2 and the gold standard auscultatory measurements over a 31-day calibration interval, including evaluation of measurement stability and response to induced blood pressure changes.
monitoring over a period of 31 days; to evaluate the performance of the Corsano CardioWatch 287-2.
|
31 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Assess usability
Časové okno: 31 days
|
The secondary objective of this study is to assess the usability of the Corsano CardioWatch 287-2 from a patient perspective in a remote care setting.
This will be done by using a questionnaire that assesses the usability, comfort, and noticeability of wearing the CardioWatch 287-2.
|
31 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- COR-BP
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .